Table 1.

Patient characteristics (safety analysis set)

Characteristic	Safety analysis set (N = 821)a
Age, years
Median (range)	53 (4–75)
Mean ± SD	49.75 ± 14.32
Unknown	14 (1.71)
Sex
Male	486 (59.20)
Female	335 (40.80)
Number of transplants
1	670 (81.61)
≥2	149 (18.15)
Unknown	2 (0.24)
Length of hospital stay after first transplantation, daysb
Median (range)	87.0 (17–482)
Mean ± SD	102.3 ± 57.1
Unknown	28 (3.41)
Primary reason for HSCT
Acute myeloid leukemia	311 (37.88)
Acute lymphoblastic leukemia	155 (18.88)
Myelodysplastic syndrome	116 (14.13)
Lymphoid malignant tumor	105 (12.79)
Other diseases	133 (16.20)
CMV antibody combination
R+/D+	287 (34.96)
R+/D−	273 (33.25)
R−/D+	39 (4.75)
R−/D−	32 (3.90)
Unknown	190 (23.14)
Stem cell source
Cord blood	283 (34.47)
Bone marrow	277 (33.74)
Peripheral blood	259 (31.55)
Donor type
Allogeneic transplantation	818 (99.63)
Related	243 (29.60)
Sibling	147 (17.90)
Other sibling	88 (10.72)
Unrelated	575 (70.04)
Autologous transplantation	1 (0.12)
Unknown	2 (0.24)
HLA
Matched	266 (32.40)
Mismatched	527 (64.19)
Mismatched excluding haploidentical	417 (50.79)
Haploidentical	110 (13.40)
Other	2 (0.24)
Unknown	26 (3.17)
Conditioning regimen
Myeloablative transplantation	389 (47.38)
Anti-thymocyte globulin	140 (17.05)
T-cell depletion or CD34(+) selected HSCT	9 (1.10)
Pre-transplantation corticosteroid use	390 (47.50)
GVHD prophylaxis
Yes	795 (96.83)
No	2 (0.24)
Unknown	24 (2.92)
Drugs used for GVHD prophylaxis (>5%)c
Tacrolimus	646 (78.68)
Methotrexate	598 (72.84)
Mycophenolate mofetil	163 (19.85)
Cyclosporine	139 (16.93)
Cyclophosphamide	58 (7.06)

HSCT hematopoietic stem cell transplantation, GVHD graft versus host disease